MedTrace Logo

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06999434 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2025-05-31

No results posted yet for this study

Summary

The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

Conditions

  • Demyelinating Disorders
  • MCI
  • Alzheimer's Disease (AD)
  • MS (Multiple Sclerosis)
  • SCI - Spinal Cord Injury
  • Spinal Radiculopathy

Interventions

DRUG

[ 18F]3F4AP

PET Scan #3

DRUG

[18F]MK6240

PET Scan #2

DRUG

[11C]PIB

PET Scan #1

Sponsors & Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)

    collaborator NIH

  • National Institute on Aging (NIA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Georges El Fakhri, PhD, DABR · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2030-05-05
Completion
2030-05-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06999434 on ClinicalTrials.gov